Cargando…

Rapid Detection of KPC-Producing Enterobacterales Susceptible to Imipenem/Relebactam by Using the MALDI-TOF MS MBT STAR-Carba IVD Assay

KPC-producing Enterobacterales represent a serious public health concern. Limited therapeutic options are available for treatment, however, the novel combination of imipenem/relebactam represents a promising alternative. To preserve the activity of this new antibiotic combination, only targeted trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oviaño, Marina, Gato, Eva, Bou, Germán
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058919/ https://www.ncbi.nlm.nih.gov/pubmed/32184776 http://dx.doi.org/10.3389/fmicb.2020.00328

Ejemplares similares

Performance Evaluation of the MBT STAR(®)-Carba IVD Assay for the Detection of Carbapenemases With MALDI-TOF MS
por: Anantharajah, Ahalieyah, et al.
Publicado: (2019)

Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
por: García-Fernández, Sergio, et al.
Publicado: (2023)

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
por: Papp-Wallace, Krisztina M., et al.
Publicado: (2023)

2160. Emergence of INDEL Mutations in KPC-2: Insights into Ceftazidime-Avibactam and Imipenem-Relebactam Efficacy
por: Brunetti, Florencia, et al.
Publicado: (2023)

Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacterales: The Future of Networking Data Analysis With Online Software
por: Gato, Eva, et al.
Publicado: (2022)

Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)
por: Hernández-García, Marta, et al.
Publicado: (2022)

Analysis of the Degradation of Broad-Spectrum Cephalosporins by OXA-48-Producing Enterobacteriaceae Using MALDI-TOF MS
por: Oviaño, Marina, et al.
Publicado: (2019)

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland
por: Nordmann, Patrice, et al.
Publicado: (2023)

1080. Relebactam Increases Imipenem Activity Against Imipenem-Nonsusceptible and -Susceptible Pseudomonas aeruginosa and Enterobacterales: Assessment of Isolates from RESTORE-IMI 2
por: Hilbert, David W, et al.
Publicado: (2021)

Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa
por: López-Pérez, Mario, et al.
Publicado: (2021)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
por: Mashaly, Mervat El-Sayed, et al.
Publicado: (2021)

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020
por: Karlowsky, James A., et al.
Publicado: (2023)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
por: Bonnin, Rémy A., et al.
Publicado: (2023)

Identification of Nocardia and non‐tuberculous Mycobacterium species by MALDI‐TOF MS using the VITEK MS coupled to IVD and RUO databases
por: Rodríguez‐Temporal, David, et al.
Publicado: (2022)

Direct Detection of Carbapenemase-Producing Klebsiella pneumoniae by MALDI-TOF Analysis of Full Spectra Applying Machine Learning
por: Gato, Eva, et al.
Publicado: (2023)

Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient
por: Gaibani, Paolo, et al.
Publicado: (2022)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates
por: Rogers, Tara M, et al.
Publicado: (2023)

Poor Sensitivity of the MALDI Biotyper(®) MBT Subtyping Module for Detection of Klebsiella pneumoniae Carbapenemase (KPC) in Klebsiella Species
por: Cuello, Luz, et al.
Publicado: (2023)

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative
por: Castanheira, Mariana, et al.
Publicado: (2021)

2152. Activity of Imipenem/Relebactam Against Carbapenem-Resistant Non-Morganellaceae Enterobacterales (NME) in the United States – SMART 2019-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus
por: Lopeman, Rose C., et al.
Publicado: (2020)

Multicenter Evaluation of Rapid BACpro(®) II for the Accurate Identification of Microorganisms Directly from Blood Cultures Using MALDI-TOF MS
por: Oviaño, Marina, et al.
Publicado: (2021)

Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase
por: Bovo, Federica, et al.
Publicado: (2023)

Carbapenemase Producing Klebsiella pneumoniae (KPC): What Is the Best MALDI-TOF MS Detection Method
por: Hleba, Lukáš, et al.
Publicado: (2021)

1718. In Vitro Activity of Imipenem/Relebactam against Class C β-lactamase-Positive Enterobacterales in the Asia/Pacific Region: SMART 2018-2020
por: Lob, Sibylle, et al.
Publicado: (2022)

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021)

A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date
por: Campanella, Toni A, et al.
Publicado: (2020)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
por: Kurihara, Dai, et al.
Publicado: (2022)

Machine learning model of imipenem‐resistant Klebsiella pneumoniae based on MALDI‐TOF‐MS platform: An observational study
por: Zeng, Yu, et al.
Publicado: (2023)

Evaluation of Rapid Sepsityper® protocol and specific MBT-Sepsityper module (Bruker Daltonics) for the rapid diagnosis of bacteremia and fungemia by MALDI-TOF-MS
por: Ponderand, Léa, et al.
Publicado: (2020)

2153. Addition of Relebactam Increases Susceptibility to Imipenem Alone against Class C β-lactamase-Positive Enterobacterales: Asia/Pacific SMART 2019-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

Multicentre study on the reproducibility of MALDI-TOF MS for nontuberculous mycobacteria identification
por: Rodriguez-Temporal, David, et al.
Publicado: (2022)

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020
por: Bovo, Federica, et al.
Publicado: (2022)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
por: Young, Katherine, et al.
Publicado: (2019)

Author Correction: Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus
por: Lopeman, Rose C., et al.
Publicado: (2020)

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections
por: Bhagunde, Pratik, et al.
Publicado: (2019)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
por: Jang, Soo Min, et al.
Publicado: (2021)

Direct Detection of KPC Peak from Positive Blood Cultures Using MALDI-TOF MS: Are We There Yet?
por: Moreira, Natália Kehl, et al.
Publicado: (2023)

Rapid, Easy, and Reliable Identification of Nocardia sp. by MALDI-TOF Mass Spectrometry, VITEK(®)-MS IVD V3.2 Database, Using Direct Deposit
por: Hodille, Elisabeth, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m3eg6lvs5v3uq6c9s9qkha49q9